References
- Solomon T , Lewthwarte P , Perera D , et al. Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect Dis 2010;10(11):778-90
- Yip CCY , Lau SKP , Woo PCY , Yuen KY . Human enterovirus 71 epidemics: what’s next? Emerg Health Threats J 2013;6:19780
- Mao Q , Wang Y , Yao X , et al. Coxsackievirus A16: epidemiology, diagnosis and vaccine. Hum Vaccin Immunother 2014;10(2):360-7
- Cheng A , Fung CP , Liu CC , et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013;31:2471-6
- Zhu PC , Meng FY , Li JX , et al. Efficacy, safety, and immunology of an inactivated alum-adjuvanted enterovirus 71 vaccine in children in Mainland China: a multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet 2013;381(9882):2024-32
- Zhu F , Xu W , Xia J , et al. Efficacy safety and immunogenicity of an enterovirus 71 vaccine in Mainland China. N Engl J Med 2014;370(9):818-28
- Li R , Liu L , Mo Z , et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014;370(9):829-37
- Liu CC , Chow YH , Chong P , Klein M . Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine 2014. [Epub ahead of print]
- Kung YA , Hung CT , Liu YC , Shih SR . Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther 2014;14(10):1455-64
- Xing W , Liao Q , Viboud C , et al. Hand, foot, and mouth disease in Mainland China, 2008-12: an epidemiological study. Lancet Infect Dis 2014;14(4):308-18
- Chong P , Hsieh SY , Liu CC , et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother 2012;8(12):1775-83
- Chou AH , Liu CC , Chang JY , et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol 2012;831282
- Chou AH , Liu CC , Chang JY , et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody responses against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013;8(11):e79783
- Shenyu W , Jingxin L , Zhenglun L , et al. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized. double-blind, placebo-controlled clinical trial. J Infect Dis 2014;210(7):1073-82
- Han JF , Cao RY , Deng YQ , et al. Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo. Virol J 2011;8:106-13
- Lin CW , Liu CC , Lu TC , et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed Res Int 2014;670506
- Chen JF , Zhang RS , Ou XH , et al. The role of enterovirus 71 and coxsackievirus A strains in a large outbreak of hand, foot and mouth disease in 2012 in Changsha, Mainland China. Int J Infect Dis 2014;28C:17-25
- Wu Y , Yeo A , Phoon MC , et al. The largest outbreak of hand, foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14(12):e1076-81
- Lu QB , Zhang XA , Wo Y , et al. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in Mainland China, 2009-2011. PLoS One 2012;7(12):e52073
- Di B , Zhang Y , Xie H , et al. Circulation of Coxsackievirus A6 in hand-foot-mouth disease in Guanzhou, 2010-2012. Virol J 2014;11:157-63
- Mirand A , Henquell C , Archimbaud C , et al. Outbreak of hand foot and mouth disease/herpangina associated with coxsackie A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect 2012;18(5):E110-18
- Wang YF , Yu CK . Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 2014;21:31-41
- Lin YW , Yu SL , Shao H , et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013;8(2):e57591
- Lee BY , Wateska A , Bailey RR , et al. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine 2010;28(49):7731-6